Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? Source: Eur Respir J 2014; 43: 1201-1203 Year: 2014
Dissecting COPD exacerbations: time to rethink our definition Source: Eur Respir J, 50 (3) 1701432; 10.1183/13993003.01432-2017 Year: 2017
COPD: still an unpredictable journey Source: Eur Respir J, 57 (3) 2002933; 10.1183/13993003.02933-2020 Year: 2021
Finding the true prevalence of obstructive lung disease: two steps forward and one step back Source: Eur Respir J, 55 (6) 2001514; 10.1183/13993003.01514-2020 Year: 2020
Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial. Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017
The future of bronchodilation: looking for new classes of bronchodilators Source: Eur Respir Rev, 28 (154) 190095; 10.1183/16000617.0095-2019 Year: 2019
Beta-blockers in COPD: time for reappraisal Source: Eur Respir J 2016; 48: 880-888 Year: 2016
Evolving use of long-term NIV in COPD: Are we getting it right Source: Annual Congress 2013 –Long-term NIV: COPD, sleep, obesity and outcomes Year: 2013
Important attributes of COPD exacerbations: a conjoint analysis Source: Eur Respir J 2004; 24: Suppl. 48, 514s Year: 2004
Late Breaking Abstract - Influence of salbutamol use on symptomatic outcomes with maintenance bronchodilators: a pre-specified analysis of the EMAX trial Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019
Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020
Hypoxaemia in COPD: looking beyond the lungs Source: Breathe 2009; 5: 363-370 Year: 2009
The future of COPD treatment: what are the difficulties in and barriers to drug development for COPD Source: Annual Congress 2011 - Lancet / ERS symposium - New frontiers in COPD Year: 2011
Methods for therapeutic trials in COPD: lessons from the TORCH trial Source: Eur Respir J 2009; 34: 1018-1023 Year: 2009
The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Mucolytics for COPD: negotiating a slippery slope towards proof of efficacy Source: Eur Respir J, 50 (4) 1701465; 10.1183/13993003.01465-2017 Year: 2017
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014